357 related articles for article (PubMed ID: 34875674)
21. The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ; Madden SF; Fay J; Collins DM; Kay EW; Sheehan KM; Furney S; Moran B; Fagan A; Morris PG; Teiserskiene A; Hill AD; Grogan L; Walshe JM; Breathnach O; Power C; Duke D; Egan K; Gallagher WM; O'Donovan N; Crown J; Toomey S; Hennessy BT
Breast Cancer Res Treat; 2021 Jun; 187(3):635-645. PubMed ID: 33983492
[TBL] [Abstract][Full Text] [Related]
22. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
[TBL] [Abstract][Full Text] [Related]
23. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
Sutton EJ; Onishi N; Fehr DA; Dashevsky BZ; Sadinski M; Pinker K; Martinez DF; Brogi E; Braunstein L; Razavi P; El-Tamer M; Sacchini V; Deasy JO; Morris EA; Veeraraghavan H
Breast Cancer Res; 2020 May; 22(1):57. PubMed ID: 32466777
[TBL] [Abstract][Full Text] [Related]
24. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
26. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
27. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
28. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
29. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
[TBL] [Abstract][Full Text] [Related]
30. The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.
Yang G; Lu T; Weisenberger DJ; Liang G
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140723
[TBL] [Abstract][Full Text] [Related]
31. Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
Sakaguchi A; Horimoto Y; Onagi H; Ikarashi D; Nakayama T; Nakatsura T; Shimizu H; Kojima K; Yao T; Matsumoto T; Ogura K; Kitano S
Breast Cancer Res; 2021 Oct; 23(1):99. PubMed ID: 34715905
[TBL] [Abstract][Full Text] [Related]
32. Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
Dell'Aquila K; Vadlamani A; Maldjian T; Fineberg S; Eligulashvili A; Chung J; Adam R; Hodges L; Hou W; Makower D; Duong TQ
Breast Cancer Res; 2024 Jan; 26(1):7. PubMed ID: 38200586
[TBL] [Abstract][Full Text] [Related]
33. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
34. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
35. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
36. Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer.
Hacking SM; Karam J; Singh K; Gamsiz Uzun ED; Brickman A; Yakirevich E; Taliano R; Wang Y
Pathol Res Pract; 2023 Jun; 246():154476. PubMed ID: 37146413
[TBL] [Abstract][Full Text] [Related]
37. Texture analysis using machine learning-based 3-T magnetic resonance imaging for predicting recurrence in breast cancer patients treated with neoadjuvant chemotherapy.
Eun NL; Kang D; Son EJ; Youk JH; Kim JA; Gweon HM
Eur Radiol; 2021 Sep; 31(9):6916-6928. PubMed ID: 33693994
[TBL] [Abstract][Full Text] [Related]
38. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.
Verma C; Kaewkangsadan V; Eremin JM; Cowley GP; Ilyas M; El-Sheemy MA; Eremin O
J Transl Med; 2015 Jun; 13():180. PubMed ID: 26040463
[TBL] [Abstract][Full Text] [Related]
39. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Montagna E; Bagnardi V; Viale G; Rotmensz N; Sporchia A; Cancello G; Balduzzi A; Galimberti V; Veronesi P; Luini A; Mastropasqua MG; Casadio C; Sangalli C; Goldhirsch A; Colleoni M
Ann Oncol; 2015 Feb; 26(2):307-13. PubMed ID: 25411418
[TBL] [Abstract][Full Text] [Related]
40. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
Jiang M; Li CL; Luo XM; Chuan ZR; Lv WZ; Li X; Cui XW; Dietrich CF
Eur J Cancer; 2021 Apr; 147():95-105. PubMed ID: 33639324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
